Biotech Values

[DewDiligence]

(MNTA)—US Supreme Court rejects TEVA’s motion for a preliminary injunction against NVS/MNTA and MYL launches of generic Copaxone:

http://in.reuters.com/article/2014/04/18/us-usa-court-teva-pharm-ind-idINBREA3H0RI20140418

The USSC’s ruling on the Copaxone patent case per se will come in the Court’s next term (after 10/1/14).

Technically, Teva’s request was for the USSC to stay the CAFC’s ruling invalidating the ‘808 Copaxone patent (which expires on 9/1/15), pending review of the CAFC decision by the USSC; however, Teva’s motion was tantamount to a request for a preliminary injunction to block the launch of generic Copaxone.

NVS/MNTA (and MYL) will now almost certainly launch generic Copaxone “at risk” as soon as they obtain FDA approval.

MNTA's stock should be up sharply on Monday.